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OBJECTIVE—Leptin is an adipocyte hormone that plays a
major role in energy balance. Leptin receptors in the hypothala-
mus are known to signal via distinct mechanisms, including
signal transducer and activator of transcription-3 (STAT3) and
phosphoinositol-3 kinase (PI 3-kinase). Here, we tested the
hypothesis that extracellular signal–regulated kinase (ERK) is
mediating leptin action in the hypothalamus.
RESEARCH DESIGN AND METHODS—Biochemical, phar-
macological, and physiological approaches were combined to
characterize leptin activation of ERK in the hypothalamus in rats.
RESULTS—Leptin activates ERK1/2 in a receptor-mediated
manner that involves JAK2. Leptin-induced ERK1/2 activation
was restricted to the hypothalamic arcuate nucleus. Pharmaco-
logical blockade of hypothalamic ERK1/2 reverses the anorectic
and weight-reducing effects of leptin. The pharmacological an-
tagonists of ERK1/2 did not attenuate leptin-induced activation of
STAT3 or PI 3-kinase. Blockade of ERK1/2 abolishes leptin-
induced increases in sympathetic nerve trafﬁc to thermogenic
brown adipose tissue (BAT) but does not alter the stimulatory
effects of leptin on sympathetic nerve activity to kidney, hind-
limb, or adrenal gland. In contrast, blockade of PI 3-kinase
prevents leptin-induced sympathetic activation to kidney but not
to BAT, hindlimb, or adrenal gland.
CONCLUSIONS—Our ﬁndings indicate that hypothalamic ERK
plays a key role in the control of food intake, body weight, and
thermogenic sympathetic outﬂow by leptin but does not partici-
pate in the cardiovascular and renal sympathetic actions of
leptin. Diabetes 58:536–542, 2009
L
eptin is a largely adipocyte-derived hormone that
can act in the central nervous system to decrease
appetite and increase energy expenditure,
thereby leading to decreased body weight (1).
Central actions of leptin play an important role in the
regulation of several other physiological functions, includ-
ing reproductive function (2), bone formation (3), and
regional sympathetic nerve activity (SNA) subserving ther-
mogenic metabolism and cardiovascular function (4).
Leptin exerts its effects via interaction with speciﬁc
receptors located in distinct classes of neurons. While
several isoforms of the leptin receptor have been identi-
ﬁed, the Ob-Rb form that includes the long intracellular
domain that has signaling capacity appears to mediate
most of the biological effects of leptin (5,6). The signal
transducer and activator of transcription-3 (STAT3) path-
way was the ﬁrst signaling mechanism associated with the
leptin receptor (7). Neural-speciﬁc inactivation of STAT3
leads to hyperphagia and obesity in mice (8). In addition,
disrupting the ability of the leptin receptor to activate the
STAT3 pathway in mice leads to severe obesity and several
other neuroendocrine abnormalities (9–11). More re-
cently, other intracellular signaling mechanisms, including
phosphoinositol-3 kinase (PI 3-kinase) (12), AMP-acti-
vated protein kinase (13), and mammalian target of rapa-
mycin (14), have been shown to play an important role in
the action of leptin on food intake.
Extracellular signal–regulated kinase (ERK), a member
of the mitogen-activated protein kinase (MAPK) family, is
an additional downstream pathway of the leptin receptor
(15). Leptin was shown to activate ERK1/2 in a time- and
dose-dependent manner in cultured cells (16–18). Activa-
tion of ERK1/2 by leptin seems to be mediated through Src
homology–containing tyrosine phosphatase 2 (Shp2) em-
anating from the tyrosine 985 (Tyr985) of the leptin
receptor (19,20). Stimulation of ERK by leptin can also be
achieved by direct interaction with Jak2 (15,19,20). In turn,
in cell lines, ERK appears to mediate the activation of c-fos
(20) and ribosomal S6 kinase and S6 (21) by the leptin
receptor.
This ERK pathway has been reported to mediate leptin
effects in several tissues, including cardiomyocytes
(22,23), the immune system (24,25), and kidney (26).
However, the physiological signiﬁcance of this pathway
for the hypothalamic-mediated effects of leptin remains
poorly characterized. This study depicts the effect of leptin
on hypothalamic ERK and investigates the potential role of
this ERK pathway in mediating the effect of leptin on food
intake, body weight, and regional sympathetic outﬂow.
RESEARCH DESIGN AND METHODS
Male Sprague-Dawley rats and lean and obese Zucker (fa) rats were obtained
from Harlan Sprague-Dawley. Rats were housed at 23°C with a 12-h light/dark
cycle (light on at 6:00 A.M.) and allowed free access to standard rat chow and
water. Rats receiving injections in the third cerebral ventricle were equipped
with intracerebroventricular cannulas at least 1 week before the experimen-
tation as described previously (27). Ethical approval of all of the studies was
granted by the University of Iowa Animal Research Committee.
Biochemical studies. Rats were fasted overnight before intracerebroventric-
ular administration of murine leptin (R&D Systems). Rats were killed at the
indicated time points by CO2 asphyxiation. The mediobasal hypothalamus was
quickly removed from each rat, and the total proteins were extracted and
stored at 80°C. Protein samples of homogenized tissues or immunoprecipi-
tates [to assess the effect of leptin on PI 3-kinase, immunoprecipitates were
obtained by incubating protein samples with anti–IRS-1 antibody (E-12; Santa
Cruz Biotechnology) in the presence of protein A–sepharose] were resolved
with 10% SDS-PAGE, and PVDF membranes were incubated with speciﬁc
antibodies for STAT3 (C-20; Santa Cruz Biotechnology), phospho-STAT3
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536 DIABETES, VOL. 58, MARCH 2009(Tyr705; Cell Signaling), ERK1/2 (Cell Signaling), phospho-ERK1/2 (Thr202/
Tyr204; Cell Signaling), p38 MAPK (H-147; Santa Cruz Biotechnology), phos-
pho-p38 MAPK (Thr180/Tyr182; Cell Signaling), or PI 3-kinase p85 (Cell
Signaling). Blots were detected with enhanced chemiluminescence, and their
intensity was measured for quantitative analysis. To examine the effect of
JAK2 blockade on the increase in ERK1/2 phosphorylation induced by leptin,
different doses of AG490 were administered intracerebroventricularly 1 h
before leptin (10 g). To assess the effect of leptin on p38 MAPK in the
skeletal muscle, rats were injected intraperitoneally with leptin (1 g/g body
wt) and killed 10 min after the treatment. Skeletal muscle from the hindlimb
was removed, and the extracted proteins were assayed for phospho-p38
MAPK as described above.
Immunohistochemistry. Rats were fasted overnight and treated with vehicle
or leptin either intracerebroventricularly (10 g) or intraperitoneally (1 g/g
body wt). Five to 20 min after the treatment, rats were killed by CO2
asphyxiation and then perfused transcardially with PBS followed by 4%
paraformaldehyde in PBS. The brains were removed and postﬁxed in 4%
paraformaldehyde at 4°C overnight. Fixed brains were washed three times
with PBS and incubated in 30% sucrose in PBS. Coronal sections (30 m) were
cut with a freezing Microm cryostat. Free-ﬂoating sections were washed with
PBS and permeabilized with 0.1% Triton X-100 in PBS. Sections were then
incubated overnight at 4°C with a mouse phospho-ERK antibody (1:100;
sc-7383; Santa Cruz Biotechnology) in 0.2% goat serum followed by 1-h
incubation at room temperature with a secondary antibody, rhodamine
(TRITC)-conjugated donkey anti-mouse IgG (1:100; Jackson ImmunoResearch
Laboratories).
For double labeling, brains sections were processed for the localization of
phospho-ERK as above. Rabbit antibodies recognizing proopiomelanocortin
(POMC; 1:50; Phoenix Pharmaceuticals) or neuropeptide Y (NPY; 1:50; Chemi-
con International) were used to identify the neurons in which leptin activates
ERK. Biotin-SP–conjugated donkey anti-rabbit IgG (1:100; Jackson Immu-
noResearch Laboratories) was used as secondary antibody. Primary antibod-
ies were tested separately before performing the double immunostaining.
Additional control experiments consisted in the omission of primary or
secondary antibodies in each case.
Further processing for immunodetection was performed using kits (Vector
Laboratories) following the manufacturer’s instruction. Slices were mounted
on slides, coverslipped, and visualized using a Nikon eclipse E600 ﬂuores-
cence microscope equipped with a SPOT RT digital camera.
Food intake and body weight studies. Food was removed from the
individually caged rats the day before the study. Rats were given a single
intracerebroventricular injection of PD98059 (5 g), U0126 (7 g), vehicle
(DMSO; 2 l), or artiﬁcial cerebrospinal ﬂuid (2 l) followed 15 min later by
an intraperitoneal administration of leptin (1 g/g body wt) or vehicle (saline)
or an intracerebroventricular injection of 5 g Melatonan II (MTII) or
corticotrophin-releasing factor. The doses of the various drugs were based on
our previous studies (27,28). Food was returned 1 h after the last injection
corresponding to the onset of the dark cycle. Food intake and body weight
were then recorded after 4 and 24 h.
Study of the sympathetic nervous system. Anesthetized rats were instru-
mented for direct multiﬁber recording of regional SNA as described previously
(27,28). Brown adipose tissue (BAT) SNA was recorded simultaneously with
SNA to kidney, hindlimb, or adrenal gland. After baseline recordings of SNA
were obtained, each animal received two intracerebroventricular injections.
Rats received ﬁrst PD98059 (5 g), U0126 (7 g), LY294002 (5 g), or vehicle
(DMSO; 2 l) followed 15 min later by leptin (10 g) or saline. After
intracerebroventricular administration of experimental agents, SNA measure-
ments were made every 15 min for 6 h. The data for SNA are expressed as
percentage change from baseline.
Statistical analysis. All results are expressed as means  SE and analyzed
using Student’s t test, one- or two-way ANOVA. When ANOVA reached
signiﬁcance, a post hoc comparison was made using Bonferroni or Newman-
Keuls test. A value of P  0.05 was considered to be statistically signiﬁcant.
RESULTS
To investigate the hypothesis that the ERK pathway is
important for leptin action in the central nervous system,
we ﬁrst assessed whether leptin activates this enzyme in
the hypothalamus, in vivo. The effect of intracerebroven-
tricular administration of leptin on the activity of STAT3
and ERK1/2 in the hypothalamus was examined in
Sprague-Dawley rats. As previously reported (7,12,13),
leptin caused a robust activation of the STAT3 in medio-
basal hypothalamic extracts (Fig. 1A). Leptin also caused
a rapid activation of hypothalamic ERK1/2 with a maxi-
mum effect at 5–15 min (Fig. 1B), consistent with previous
ﬁndings (29,30). This response was dose dependent (5 and
10 g leptin increased ERK1/2 activity by 3.4- and 4.3-fold,
respectively). In peripheral tissues, such as the skeletal
muscle, leptin has been shown to activate different iso-
forms of MAPK (31). Therefore, we examined whether
leptin alters the activity of another hypothalamic isoform
of MAPK. Leptin did not affect the activity of p38 MAPK in
the hypothalamus (Fig. 1C). Intraperitoneal (IP) adminis-
tration of leptin (1 g/g body wt) did, however, cause a
3.1-fold increase (P  0.01) in p38 MAPK in skeletal
muscle (data not shown).
Leptin activation of ERK1/2 appears to be mediated by
the leptin receptor because it activates hypothalamic
ERK1/2 in the Zucker lean rat, but not in the leptin
receptor–deﬁcient obese Zucker rat (Fig. 2A). Blockade of
JAK2 with AG490 inhibited, in a dose-dependent manner,
the activation of ERK1/2 by leptin (Fig. 2B), demonstrating
that the leptin receptor modulates the activity of ERK1/2
via JAK2. These data demonstrate that in the hypothala-
mus, the effect of leptin on ERK is receptor mediated,
involves JAK2, and is speciﬁc to ERK1/2 isoforms.
Within the hypothalamus, the leptin receptor has been
detected in several nuclei, including the arcuate, ventro-
medial, paraventricular, and dorsomedial nuclei (32,33).
We used an immunohistochemical approach to identify the
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FIG. 1. Leptin activation of STAT3 and ERK in the hypothalamus. Time course of activation of STAT3 (A) and ERK1/2 (B) in mediobasal
hypothalamic explants after intracerebroventricular administration of murine leptin (10 g) in rat. C: Lack of effect of intracerebroventricular
leptin on the phosphorylation of hypothalamic p38 MAPK. Data represent means  SE; n  5 rats per group. *P < 0.001 vs. vehicle; †P < 0.001
vs. leptin alone.
K. RAHMOUNI AND ASSOCIATES
DIABETES, VOL. 58, MARCH 2009 537hypothalamic nuclei in which ERK1/2 is activated by
leptin. Both systemic and central administration of leptin
caused a marked increase in the immunoreactive ERK1/2
in the arcuate nucleus (Fig. 3A). In contrast, no increase in
ERK activity was observed in hypothalamic nuclei other
than the arcuate nucleus (in Fig. 3B, the paraventricular
nucleus is shown as an example) or in extrahypothalamic
nuclei, including the nucleus tractus solitarii in the brain-
stem (data not shown). These data suggest that leptin
activation of hypothalamic ERK1/2 is selectively localized
in the arcuate nucleus.
Two classes of neurons account for leptin sensitivity
within the arcuate nucleus (32–34): ﬁrst, a catabolic path-
way represented mainly by POMC neurons that is acti-
vated by leptin; and second, an anabolic pathway
represented principally by the NPY neurons that is inhib-
ited by leptin. We therefore used double staining to
determine whether activation of ERK1/2 by leptin occurs
in one speciﬁc neuronal population. Interestingly, all the
neurons in which the ERK1/2 immunoreactivity was in-
creased by leptin were POMC positive (supplemental Fig.
1A, available in an online appendix at http://dx.doi.org/10.
2337/db08-0822). No activation of ERK1/2 was observed in
NPY neurons (supplemental Fig. 1B). These data seem to
suggest that ERK mediates leptin action through an effect
on POMC neurons.
To test the hypothesis that ERK is crucial for the
physiological action of leptin, we assessed the effect of
ERK inhibition (PD98059 and U0126) (35–37) on the
feeding and body weight responses to leptin. We ﬁrst
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FIG. 2. Leptin activation of ERK is receptor mediated and involves JAK2. A: Intracerebroventricular leptin caused a signiﬁcant increase in the
phosphorylation of hypothalamic ERK1/2 in the Zucker lean (ZL) but not in the leptin receptor–deﬁcient Zucker obese (ZO) rats. B: AG490, an
inhibitor of JAK2, administered intracerebroventricularly caused a dose-dependent blockade of intracerebroventricular leptin-induced hypo-
thalamic ERK1/2 activation. Data represent means  SE; n  5 rats per group. *P < 0.001 vs. vehicle; †P < 0.001 vs. leptin alone.
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FIG. 3. Immunohistochemical analysis of leptin activation of ERK in the hypothalamus. Intracerebroventricular and intraperitoneal (IP) leptin
activate ERK1/2 in the arcuate nucleus (ARC; A) but not in the paraventricular nucleus (PVN; B). Five rats per treatment were examined. (Please
see http://dx.doi.org/10.2337/db08-0822 for a high-quality digital representation of this ﬁgure.)
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538 DIABETES, VOL. 58, MARCH 2009veriﬁed that baseline food intake and body weight were
not altered by the administration of the vehicle (DMSO) or
the ERK inhibitors in the third cerebral ventricle (Fig.
4A–C). Treatment with leptin at the onset of the dark
phase signiﬁcantly reduced food intake at both 4 h (Fig.
4A) and 24 h (Fig. 4B). This effect was accompanied by
decreased body weight at 24 h after treatment with leptin
(Fig. 4C). Pretreatment with the ERK inhibitors (PD98059
or U0126) reversed the decrease in food intake induced by
leptin at 4 h (Fig. 4A) and 24 h (Fig. 4B). The ability of
leptin to decrease body weight was also blocked by
PD98059 and U0126 (Fig. 4C). To exclude the possibility
that blockade of the anorectic and weight-reducing actions
of leptin by PD98059 and U0126 may be due to inhibition
of other mediators of leptin action, such as STAT3 and PI
3-kinase (which are known to play an important role in
leptin effects on food intake) (9,12), we tested the effect of
leptin on the activity of ERK1/2, STAT3, and PI 3-kinase in
the presence of PD98059 and U0126. As expected, leptin
activation of hypothalamic ERK1/2 was prevented in the
presence of PD98059 or U0126 (Fig. 5). In contrast,
stimulation of hypothalamic PI 3-kinase and STAT3 by
leptin was not affected by the presence of these inhibitors
(Fig. 5). These data demonstrate that blockade of the
effect of leptin on food intake and body weight by PD98059
and U0126 is due to inhibition of ERK1/2 and not to blockade
of leptin-induced STAT3 or PI 3-kinase activation.
Because ERK is a key enzyme for many intracellular
signaling processes, we addressed the speciﬁcity of block-
ade of leptin-induced anorexia and weight loss by testing
the feeding- and weight-reducing actions of other stimuli,
i.e., an agonist of the melanocortin receptors MTII and
corticotrophin-releasing hormone. Intracerebroventricular
MTII caused a signiﬁcant decrease in food intake and body
weight at 4 and 24 h (Fig. 4D–F; data not shown).
Intracerebroventricular pretreatment with PD98059 or
U0126 did not alter the effect of intracerebroventricular
MTII on food intake and body weight (Fig. 4D–F). In
addition, the anorectic and weight-reducing actions of
intracerebroventricular administration of corticotrophin-
releasing hormone were not affected by the ERK inhibitors
(data not shown). Together, these ﬁndings show that the
pharmacological inhibitors of ERK produce a selective
blockade of the effects of leptin and do not attenuate the
responses to other agonists, such as MTII and corticotro-
phin-releasing hormone.
Leptin stimulation of the sympathetic nervous system
regulates diverse physiological processes, including en-
ergy expenditure and cardiovascular function. The possi-
ble role of hypothalamic ERK in the control of the
sympathetic nerve trafﬁc by leptin was investigated. Intra-
cerebroventricular leptin caused regional sympathetic ac-
tivation, including increases in sympathetic nerve outﬂow
to BAT (Fig. 6A), kidney (Fig. 6C), hindlimb (Fig. 6E), and
adrenal gland (Fig. 6G). Selective inhibition of ERK pre-
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FIG. 4. Role of ERK in mediating the effect of leptin on food intake and body weight. Intracerebroventricular (ICV) administration of ERK
inhibitors PD98059 (PD; 5 g) or U0126 (U; 7 g) 15 min before intraperitoneal (IP) leptin prevents the4h( A) and 24 h (B) decrease in food
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FIG. 5. Presence of ERK inhibitors blocks speciﬁcally leptin stimula-
tion of hypothalamic ERK. Intracerebroventricular (ICV1) administra-
tion of ERK inhibitors PD98059 (PD; 5 g) or U0126 (U; 7 g) 15–20
min before intracerebroventricular (ICV2) leptin prevents the in-
crease in hypothalamic phospho-ERK1/2, but not activation of PI
3-kinase or STAT3, induced by leptin. Each blot is representative of
three to four experiments.
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DIABETES, VOL. 58, MARCH 2009 539vented leptin-induced sympathetic activation to thermo-
genic BAT (Fig. 6B). This effect of ERK inhibition on BAT
sympathetic activation to leptin was dose dependent (BAT
sympathetic activation to leptin was 183  13, 114  19,
and 14  11% in the presence of vehicle, 3 g U0126, and
7 g U0126, respectively, P  0.001). In contrast, PD98059
or U0126 did not alter renal (Fig. 6D), lumbar (Fig. 6F),
and adrenal (Fig. 6G) sympathetic nerve responses to
leptin. To examine whether the control of sympathetic
outﬂow to thermogenic BAT by leptin exclusively involves
ERK, we assessed the effect of inhibition of another
pathway that has been shown to play a major role in the
feeding and sympathetic responses to leptin, PI 3-kinase
(12,38). Inhibition of PI 3-kinase with LY294002 signiﬁ-
cantly attenuated renal sympathetic activation to leptin
(Fig. 6D), which is consistent with our previous report
(38). In contrast, PI 3-kinase inhibition with LY294002
failed to alter BAT (Fig. 6A), lumbar (Fig. 6F), or adrenal
(Fig. 6G) sympathetic nerve responses to leptin. Taken
together, these results demonstrate that leptin regulates
different regional sympathetic nerve activities through
distinct and contrasting intracellular signaling pathways
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thetic response but not to renal, lumbar, or adrenal
sympathetic nerve responses to leptin.
DISCUSSION
We have characterized a new hypothalamic signaling
mechanism of the leptin receptor. Our results show that
leptin activates ERK1/2 in the arcuate nucleus and that this
pathway contributes to leptin control of food intake, body
weight, and thermogenic sympathetic outﬂow. Hypotha-
lamic ERK appears to mediate selective leptin actions
because its inhibition prevented some but not all actions
of leptin. This suggests that modulation of the hypotha-
lamic ERK pathway could affect the metabolic actions of
leptin (appetite and thermogenic sympathetic metabolism)
without altering its sympathetic cardiovascular and renal
actions.
Previous studies have implicated hypothalamic ERK in
the regulation of energy homeostasis. Fasting was shown
to activate ERK in the hypothalamic arcuate and paraven-
tricular nuclei in mice (39,40). Fasting-induced activation
of hypothalamic ERK was reversed by re-feeding, suggest-
ing that activation of ERK in the hypothalamus is relevant
for energy balance (40). Our current ﬁndings that hypotha-
lamic ERK contributes to the actions of leptin extend the
role of this ERK pathway in the control of energy ho-
meostasis. Our results are in line with the observation that
the development of obesity in mice with neuronal-speciﬁc
ablation of Shp2 is related to the inability of leptin to
stimulate ERK (41). To study the role of neuronal Shp2,
Zhang et al. (41) used the cre-loxP system to create a
conditional Shp2 mutant allele in mice. This allowed
selective deletion of Shp2 in postmitotic forebrain neu-
rons. Surprisingly, the predominant phenotype exhibited
by this mouse model was the development of early-onset
obesity. In subsequent studies, Zhang et al. found that
leptin-induced phosphorylation of ERK1/2 in the arcuate
nucleus of hypothalamus was dramatically reduced in
mice with neuronal-speciﬁc ablation of Shp2 compared
with the controls (41). In contrast, the ability of leptin to
induce phosphorylation of arcuate STAT3 was preserved
in this mouse model. Although the signaling cascade
leading to the activation of ERK by the leptin receptor
remains unclear (15), the inability of leptin to stimulate
ERK in the absence of Shp2 suggests that this protein
mediates leptin activation of ERK. However, recent ﬁnd-
ings challenge the importance of Shp2 in mediating leptin
effects (42). This is based on the observation that in mice,
mutation of the Tyr985 of the leptin receptor that blocks
Shp2 recruitment did not recapitulate the obesity pheno-
type observed in mice in which Shp2 was deleted in the
forebrain neurons (42), suggesting that, in vivo, Jak2-
dependent mechanism may be the predominant pathway
for the stimulation of ERK by the leptin receptor.
The downstream hypothalamic pathways controlled by the
leptin receptor–ERK axis remain to be elucidated. Impor-
tantly, leptin activation of ERK seems to occur in the POMC
neurons in the arcuate nucleus of the hypothalamus, which
narrows the search for the mechanisms that are controlled
by the leptin receptor–ERK axis. However, additional studies
are needed to analyze in more detail the role of ERK in POMC
vs. NPY neurons in mediating leptin action.
A key downstream target of the POMC neurons are
neurons expressing melanocortin 4 receptors (MC4Rs)
that are activated by -melanocyte stimulating hormone
(product of POMC) (33,34). Pharmacological blockade of
MC4Rs reverses the effect of leptin on body weight and
food intake (43) and deletion of the MC4Rs leads to severe
obesity in mice (44). We have previously shown that
blockade of the brain MC4R inhibits the renal, but not the
BAT, sympathetic nerve response to leptin (27). We also
showed that leptin-induced renal sympathetic activation
is absent in the homozygous MC4R knockout mice,
demonstrating the importance of this receptor in the
control of renal sympathetic outﬂow by leptin (45). In
addition, blockade of PI 3-kinase also inhibits renal, but
not BAT, SNA. In contrast to the role of MC4R and PI
3-kinase, blockade of ERK in this study inhibited SNA to
BAT but not kidney. This supports the concept that
differential intracellular mechanisms are involved in
leptin-induced sympathetic activation to kidney and
thermogenic BAT. Sympathetic activity to BAT is ERK
dependent, whereas sympathetic activity to kidney is PI
3-kinase and MC4R dependent.
These ﬁndings are in line with the notion that leptin
controls various physiological processes through a variety
of signaling mechanisms. For instance, the STAT3 path-
way appears to be involved in mediating the effects of
leptin on food intake and energy homeostasis but not on
reproductive function, growth, or glucose homeostasis (9).
However, the relative role of each of the downstream
pathways associated with the leptin receptor in the control
of food intake by leptin remains perplexing, because
disrupting any of these pathways seems to have a pro-
found effect on leptin-induced food intake. Disruption of
the leptin receptor–STAT3 pathway causes hyperphagia in
mice (9,10), which demonstrates that STAT3 is important
for the control of food intake by leptin. In addition, the
anorectic response to leptin can be reversed by blockade
of PI 3-kinase (12,38) and ERK (present study).
Some limitations of the present study need to be
addressed. First, our conclusions regarding the role of
ERK in mediating leptin effects were based on acute
studies. Whether chronic inhibition of these signaling
pathways will result in a similar effect as in the acute
studies remains to be determined, but deletion of Shp2
is accompanied by increased food intake and obesity,
presumably through disruption of ERK signaling. Sec-
ond, the inhibitors that we used in our studies to block
ERK might have other nonspeciﬁc actions. However,
cell-based assays and in vitro studies have shown that
both PD98059 and U0126 appear to speciﬁcally suppress
ERK signaling (35–37). These inhibitors have been
widely used to suppress activation of ERK and to
examine the physiological roles of these enzymes. In
addition, we have shown that pretreatment with ERK
inhibitors did not alter leptin-induced activation of
STAT3 or PI 3-kinase and did not affect the appetite- and
weight-reducing actions of MTII and corticotrophin-
releasing hormone. Third, our studies lack the neuro-
anatomical speciﬁcity regarding the brain nuclei where
the ERK signaling pathway mediates the effects of leptin
on food intake, body weight, and BAT sympathetic
outﬂow, because the inhibitors were administered in-
tracerebroventricularly. Nonetheless, using an immuno-
histochemical approach, we have shown that leptin
activation of ERK occurs in the arcuate nucleus.
In conclusion, our experiments provide evidence that
hypothalamic ERK is a signiﬁcant downstream target for
the effects of leptin to regulate food intake, body weight,
and thermogenic sympathetic outﬂow to BAT. However,
K. RAHMOUNI AND ASSOCIATES
DIABETES, VOL. 58, MARCH 2009 541ERK does not appear to be involved in leptin activation of
the sympathetic nervous system to other tissues, such as
kidney, hindlimb, and adrenal gland. These ﬁndings provide
new insights into the intracellular mechanisms engaged by
the leptin receptor to control various physiological functions.
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